Overview

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Status:
Active, not recruiting
Trial end date:
2021-07-10
Target enrollment:
Participant gender:
Summary
A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic Fibrosis will be included in the study.
Phase:
Phase 2
Details
Lead Sponsor:
AlgiPharma AS
Collaborators:
AlgiPharma Australia Pty. Ltd.
AlgiPharma Pty Ltd
Treatments:
Alginic acid